Consensus Trevi Therapeutics, Inc.

Equities

TRVI

US89532M1018

Real-time Estimate Cboe BZX Other stock markets 12:38:12 2024-05-20 pm EDT			5-day change	1st Jan Change
2.895 ^USD	+4.51%		+8.79%	+121.64%

May. 07	Transcript : Trevi Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024
May. 07	Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on Trevi Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1d9c3697599d1562.7-_NoOc9UVgH9qp15cGiSYTpKlrHgC3aOduMfItQmz8.p9-F9YJ0YBNRp5gngPj4GOauEjy1rXTsba7AH-do806D2Z3uiXoLGUOE8w~5e04c61e81dcb0bbfdcd146581e498ab

Analyst Recommendations on Trevi Therapeutics, Inc.

B. Riley Starts Trevi Therapeutics at Buy With $6 PT, Views as Deep Value Play in Idiopathic Pulmonary Fibrosis Chronic Cough Space	23-04-12	MT
JonesTrading Initiates Trevi Therapeutics at Buy With $7 Price Target	23-03-14	MT
SVB Securities Starts Trevi Therapeutics at Outperform With $6 Price Target	22-11-22	MT
Oppenheimer Adjusts Trevi Therapeutics Price Target to $9 From $12 Mainly on Higher Discount Rate, Maintains Outperform Rating	22-11-15	MT
Needham Trims Price Target on Trevi Therapeutics to $8 From $10, Maintains Buy Rating	22-11-11	MT
Oppenheimer Adjusts Trevi Therapeutics' Price Target to $12 From $10, Maintains Outperform Rating	22-06-30	MT
Needham Adjusts Trevi Therapeutics' Price Target to $10 From $8, Reiterates Buy Rating	22-06-30	MT
Trevi Therapeutics Rises After Oppenheimer Starts Coverage With Outperform Rating	22-05-25	MT
Oppenheimer Starts Trevi Therapeutics at Outperform With $10 Price Target	22-05-25	MT
Aegis Capital Initiates Trevi Therapeutics at Buy with $10 Price Target	22-03-29	MT
Needham Adjusts Price Target on Trevi Therapeutics to $8 from $10, Keeps Buy Rating	21-11-11	MT
TREVI THERAPEUTICS : Needham Adjusts Trevi Therapeutics' Price Target to $10 from $12, Keeps Buy Rating	21-08-13	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.77 USD

Average target price

7.4 USD

Spread / Average Target

+167.15%

High Price Target

9 USD

Spread / Highest target

+224.91%

Low Price Target

6 USD

Spread / Lowest Target

+116.61%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Trevi Therapeutics, Inc.

B. Riley
JonesTrading Institutional Services
SVB Securities LLC
Oppenheimer
Needham & Co.
Aegis Capital

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar